Bad press has plagued St. Jude Medical's ICD leads since the Riata recall in December and the company is now riding out the latest wave. During the past week, the company received a surprising order from FDA to conduct studies on the recalled Riata as well as the non-recalled Durata and other leads. Then, it was dealt another public blow upon the release of a study questioning the safety of its Durata lead, which St. Jude has fervently been promoting to deflect the bad press stemming from the Riata. Read about St. Jude's latest PR headaches and other top stories of the week in our roundup below.

• Cardiologist Proves to be Thorn in St. Jude's Side for ICD Leads (MPMN)
• Doctor Cites Abrasion in New St. Jude Heart Device Wires (Minneapolis Tribune)
• St. Jude is Told to Study a Defect in Heart Devices (New York Times)
• Big Corporations Set to Outshine Startups in 'Fourth Era of Innovation' (MPMN)
• Medical Device Tax 101 (MD+DI)
• Medtronic Heart Device Sales Stabilize, but Disappoint (Reuters)
• Coming Up Next: Using an App as Prescribed (New York Times)
• FDA SpyGate: New Revelations Challenge New York Times Investigation of Agency 'Enemies List' (Forbes)